PO.ET03.05 · 实验与分子治疗

Drug Resistance 2: Tyrosine Kinase Inhibitors

27 张海报 25 张含资料时间 Apr 22 2026 9:00AM 区域 Section 11

7022 7022 研究PRMT5作为EGFR TKI耐药NSCLC的治疗靶点，并评估黏蛋白作为NSCLC血液生物标志物的作用 Investigating PRMT5 as a therapeutic target in EGFR TKI resistant NSCLC and assessing the role of mucins in NSCLC as blood biomarkers Aditya Krishnan, James Jin, Usama Altayeh, Jessica Hindenburg, Neelu Puri
7024 · PDF 同时靶向CHI3L1和PD-1/PD-L1轴以克服EGFR非小细胞肺癌的耐药性和免疫耐受 Simultaneous targeting of CHI3L1 and PD-1/PD-L1 axis to overcome drug resistance and immune tolerance of EGFR non-small cell lung cancer Suchitra Kamle, Bing Ma, Brianna Pham, Isabella Fish, Marlo Hulnick, Taka Sadanaga, Hanseok Jeong, Mara Hofstetter, Hina Khan, Christopher Azzoli, Katerina A. Politi, Roy S. Herbst, Chun Geun Lee, Jack Elias
7025 · PDF HER2突变非小细胞肺癌中zongertinib耐药机制及克服耐药的潜在策略 Mechanisms of zongertinib resistance in HER2-mutant non-small cell lung cancer and potential strategies to overcome resistance Yuji Shibata, Monique B. Nilsson, Ximeng Liu, Li (Lily) Cai, Hong Jiang, Linghzi Hong, Alvaro Guimaraes Paula, Hibiki Udagawa, Jacqulyne Ponville Robichaux, Junqin He, Xiaoxing Yu, John V. Heymach
7026 · PDF IL-1 alpha表达在HNSCC中诱导对所有代EGFR抑制剂的耐药 IL-1 alpha expression induces drug resistance to all generations of EGFR inhibitors in HNSCC Nafis Md Irfan, Ishrat Nourin Khan, Nurgul Koyuncu, Krishna Awasthi, Andrean L. Simons-Burnett
7027 · PDF EGFR突变NSCLC中通过新型keratin 17+药物耐受持留细胞群体的多谱系耐药演化 Multi-lineage evolution of drug resistance via a novel keratin 17+ drug tolerant persister population in EGFR -mutant NSCLC Benjamin B. Morris, Monique B. Nilsson, Ethan Earlie, Eric E. Gardner, Hong Chen, Santiago G. Trevino, Alexa J. Halliday, Yuanxin Xi, Jing Wang, Natalie Vokes, Don Gibbons, Jianjun Zhang, Ashley M. Laughney, Yasir Y. Elamin, Xiuning Le, John V. Heymach
7028 · PDF 研究PLK4和GDF15在NSCLC致瘤性和EGFR-TKI耐药中的作用 Investigating the role of PLK4 and GDF15 in NSCLC tumorigenicity and EGFR-TKI resistance Subaranjana Saravanaguru Vasanthi, Georgia Kapetaneas, Meet Patel, Neelu Puri
7029 · PDF 构建携带对最新一代EGFR抑制剂耐药机制的非小细胞肺癌等基因模型 Engineering isogenic models harboring resistance mechanisms to the latest-generation EGFR inhibitor in non-small cell lung cancer Hyeyoun Chang, Florencia M. Rowdo, Kirsty Wienand, John G. Foulke, Paul Lovell, Francisca Vasquez, Fang Tian
7030 · PDF 肿瘤-巨噬细胞串扰促进肺腺癌对EGFR靶向治疗的耐药 Tumor-macrophage crosstalk promotes resistance to EGFR targeted therapy in lung adenocarcinoma Philippe Gui, Victor Olivas, Tiffany Li, Whitney Tamaki, Hannah Bergo, D. Lucas Kerr, Wei Wu, Collin M. Blakely, Trever G. Bivona
7031 · PDF 瘤内牙龈卟啉单胞菌通过牙龈蛋白酶介导的IGF1R激活介导EGFR突变型肺腺癌对奥希替尼的耐药 Intra-tumoral Porphyromonas gingivalis mediates osimertinib resistance in EGFR-mutant lung adenocarcinoma through gingipain-mediated IGF1R activation Wendong Li, Mahima Raul, Keqiang Zhang, Jan Potempa, Yuanyuan Gao, Dan Raz
7032 · PDF GLAST（SLC1A3）：克服肺癌奥希替尼耐药的新型治疗靶点 GLAST (SLC1A3), a novel therapeutic target for overcoming osimertinib resistance in lung cancer Sara Bernstein, Sophie Kim, Clara Takanohashi, Beatriz P. Peixoto, Kathy Nguyen, Hiromi Inoue Wettersten
7033 · PDF 抑制PGC1b/线粒体生物合成是介导EGFR突变型NSCLC对第三代EGFR抑制剂治疗反应的关键事件 Inhibition of PGC1b/mitochondrial biogenesis as a critical event in mediating therapeutic response of EGFR mutant NSCLC to third generation EGFR inhibitors Zhen Chen, Dongsheng Wang, Songqing Fan, Qiming Wang, Suresh S. Ramalingam, Shi-Yong Sun
7034 · PDF 地喹氯铵与奥希替尼联用在克服EGFR突变型非小细胞肺癌奥希替尼获得性耐药中的潜力 The potential of dequalinium chloride and osimertinib combination in overcoming osimertinib acquired resistance in EGFR-mutant non-small cell lung cancer Jing Sun, Dongsheng Wang, Suresh S. Ramalingam, Zhen Chen, Shi-Yong Sun
7035 · PDF CD24作为EGFR突变型NSCLC奥希替尼诱导的耐药持留细胞的治疗易感性靶点 CD24 as a therapeutic vulnerability in osimertinib-induced drug-tolerant persister cells of EGFR-mutant NSCLC Ji Ae Ko, Ji Hyung Moon, Youwon Lee, Minyeop Kim, Eun Ji Lee, Seung Yeon Oh, JI WOO LIM, So Young Park, Sujin Choi, Jii Bum Lee, Min Hee Hong, Jae-Hwan Kim, Sun Min Lim, Byoung Chul Cho, Mi Ran Yun
7036 · PDF ecDNA介导的癌基因扩增是NSCLC对EGFR TKI耐药的基础 EcDNA-mediated oncogene amplification underlies EGFR TKI resistance in NSCLC Boyoon Kim, Sujin Kim, Jeonghee Cho, Hoon Kim
7037 · PDF 线粒体呼吸的磷酸化重编程是肾细胞癌舒尼替尼耐药的基础 Phospho-reprogramming mitochondrial respiration underlies sunitinib resistance in renal cell carcinoma Gianna Lee Mochi, Samhitha Adavikolanu, Julia K. Burkacki, Mark R. Woodford
7038 · PDF SIPA1L3缺失通过Rap1-MAPK激活在ALK-/RET-融合阳性NSCLC中诱导TKI耐药 SIPA1L3 loss induces TKI resistance via Rap1-MAPK activation in ALK-/RET-fusion positive NSCLC Xinzhao Wei, Jun Adachi, Ryohei Katayama
7039 · PDF FER驱动EGFR突变肺癌中耐药持留细胞的存活 FER drives drug-tolerant persister cell survival in EGFR-mutant lung cancer Bobak Parang, Rabia Khan, Ariana Kupai, Yuyun Huang, Sungyun Cho, Michal J. Nagiec, Eric E. Gardner, Florencia M. Rowdo, Benjamin D. Hopkins, Qin Fu, Sheng Zheng, Timothy F. Burns, John Blenis
7040 · PDF 癌症持留细胞对铜介导的死亡敏感化 Cancer persister cells are sensitized to copper-mediated death Anna Elizabeth Stuhlfire, August (Gus) Finley Williams, Masayoshi Higuchi, Ariel H. Nguyen, David A. Gervasio, Claire Turkal, Janani Nagasubramanya, Michael Nguyen, Suejean Chon, Matthew Hangauer
7041 · PDF 整合多组学与空间转录组学揭示肿瘤-基质共进化驱动BRAF-V600E胆管癌的dabrafenib耐药 Integrated multi-omics and spatial transcriptomics reveal tumor stroma co-evolution driving dabrafenib resistance in BRAF-V600E cholangiocarcinoma Nai-Jung Chiang, Ya-Chin Hou, Chi-Che Hsieh, Chao-Chun Cheng, Che-Hung Shen
7042 · PDF 错义突变型p53调控DNA复制与损伤反应，促进ALK融合肺腺癌对靶向治疗的耐药 Missense mutant p53 regulates DNA replication and damage response to promote resistance to targeted therapies in ALK fusion lung adenocarcinoma Esther Redin, Barbara P. Mello, Yingian A. Zhan, Nicholas Socci, Samuel Tischfield, Alexander Lim, Hong Zhong, Mark Donoghue, Richard Koche, Elisa De Stanchina, Alexander Drilon, Alvaro Quintanal-Villalonga, Charles M. Rudin
7044 · PDF 对索拉非尼耐药导致HCC中的上皮-间质转化及细胞表型改变 Resistance to sorafenib leads to epithelial-to-mesenchymal transition and alterations in cell phenotype in HCC Paulina Marona, Anna Ferenc, Isabel Fabregat, Ester Gonzales Sanchez, Esther Bertran, Javier Vaquero, Jolanta Jura, Katarzyna Miękus
7045 · PDF 多组学鉴定EMT和PI3K/AKT通路为黄芪多糖介导逆转osimertinib耐药的机制 Multi-omics identifies EMT and PI3K/AKT pathways as mechanisms for Astragalus membranaceus polysaccharide-mediated reversal of osimertinib resistance Kenneth K.W. To, Longling Wang, Zhong Zuo, William C. Cho
7046 · PDF BRAF/EGFR抑制在BRAF突变型结直肠癌中诱导ERBB2作为一种可靶向的耐受机制 BRAF/EGFR inhibition induces ERBB2 as a targetable tolerance mechanism in BRAF -mutant colorectal cancer Sara Peltola, Kari J. Kurppa, Klaus Elenius
7047 · PDF 来源于患者细胞系的TKI诱导性药物耐受持留细胞的特征分析 Characterization of TKI-induced drug-tolerant persister cells from patient-derived cell lines Floriane Braye, Inmaculada Alonso Garcia, Vincent Boursier, Ludovic Bigot, Kristi Beshiri, FRANCESCO FACCHINETTI, Jean-Paul Thiery, Benjamin Besse, Ken A. Olaussen, Luc Friboulet
7048 · PDF Neuregulin-1（NRG1）导向疗法在NRG1融合阳性癌症中诱导碱性磷酸酶胎盘型（ALPP）表达：临床前数据与治疗前景 Neuregulin-1(NRG1 ) -directed therapies induce alkaline phosphatase placental (ALPP) expression in NRG1 -fusion positive cancers: Preclinical data and therapeutic perspective Manon Barre, Clarisse Thiollier-Schmitt, Marie Issenmann, Célia Cortay, Emeline Cros-Perrial, Sandra Ortiz-Cuaran, Nicolas Gadot, Elodie Voilin, Sylvie Lantuejoul, Anthony Ferrari, Eric Cumunel, Charles Dumontet, Lars Petter Jordheim, Michael Duruisseaux
7049 · PDF 全基因组CRISPR-Cas9筛选鉴定肝细胞癌中赋予lenvatinib耐药的基因 Genome-wide CRISPR-Cas9 screen identifies genes conferring lenvatinib resistance in hepatocellular carcinoma Ayumu Taguchi, Shuang Zhou, Hisanori Isomura, Haruki Mori, Toru Miyake, Yuichi Abe, Miyako Tanaka, Seiji Natsume, Masataka Okuno, Waki Hosoda, Masaji Tani, Takayoshi Suganami
7050 7050 由circSOD2编码的一种新型149氨基酸蛋白抑制铁死亡并促进膀胱癌顺铂耐药 A novel 149-amino acid protein encoded by circSOD2 inhibits ferroptosis and promotes cisplatin resistance in bladder cancer Shanqi Guo, Zhihong Lv, Nan Wang, Xingkang Jiang

在会议检索中浏览本分会场